PartnersMasters has collaborated with Thornton & Ross (T&R) UK to initiate a global NPS programme for a new topical treatment for Mastocytosis patients in the UK and worldwide. The topical treatment is a 4% Sodium Cromoglycate Cutaneous Emulsion (SCGCE) and has been clinically researched in atopic dermatitis by Dr Alan Edwards and colleagues and published in the British Journal of Dermatology in February 2005. Cutaneous Mastocytosis is a debilitating condition affecting both adults and children, the symptoms of which can be helped by topical application of SCG.
SCGCE is currently undergoing Phase 3 clinical trial in the UK. In a previously completed randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical study the compound was administered for 12 weeks to 114 child subjects with moderately severe atopic dermatitis. In the study results, published in the British Journal of Dermatology in February 2005, SCGCE demonstrated a statistically significant reduction in symptoms. During the study, subjects were permitted to continue with their existing treatment, in most cases this consisted of emollients and topical steroids. A positive secondary outcome of the study was a reduction in the use of topical steroids for the SCGCE-treated subjects.
SCGCE is an innovative topical formulation of cromolyn sodium, a widely used molecule with a well established safety profile. With the principle of patient care in mind, this collaboration will help provide individual access of an important treatment for patients with Mastocytosis.